Summary of Key Points Core Viewpoint - The Hong Kong Stock Exchange (HKEX) saw 11 companies submit applications for listing from June 30 to July 6, with no companies passing the listing hearing during this period. Additionally, 7 companies initiated their public offerings, and 5 new stocks were listed. Group 1: Companies Submitting Applications - Puxiang Health Holdings Limited is a leading provider of integrated medical and elderly care services in North China, ranking second in revenue among its peers and first in revenue growth from 2022 to 2024 [2] - Magnesium Health Technology Co., Ltd. focuses on innovative payment solutions for medical expenses, being the largest provider of innovative health insurance solutions in China by policy count [3] - Yangtuo Technology Inc. operates a trading and service platform for home care and nutrition products, holding a 10.1% market share in the low-tier market [4] - Xiamen Ruiwei Information Technology Co., Ltd. specializes in image intelligent analysis products and solutions, leveraging machine learning and computer vision technologies [5] - Zijin Gold International Limited is a leading global gold mining company, ranking ninth in gold reserves and eleventh in production as of 2024 [6] - EVE Energy Co., Ltd. is a leading lithium battery platform company, ranking first in China for consumer cylindrical battery shipments and second globally for energy storage battery shipments [7] - Zhejiang Yifei Intelligent Technology Co., Ltd. is a leading industrial robotics company in China, focusing on the light industry [8] - ChipMight Semiconductor Technology (Hangzhou) Co., Ltd. is a leading power semiconductor company, ranking second in the global OLED display PMIC market [9] - Beijing Tongrentang Medical Investment Co., Ltd. is the largest non-public Chinese medicine hospital group by outpatient and inpatient visits [11] - Shandong Linglong Tire Co., Ltd. is the largest OE tire manufacturer in China and the third largest globally [12] - Magnesium Holdings Limited is an innovative automotive technology company focused on AI-driven integrated domain control solutions [13] Group 2: Public Offerings and New Listings - Seven companies initiated their public offerings, including Anjii Foods, which had a subscription rate of 44.2 times for its public offering [14][15] - Other companies like Lens Technology and Fortior also initiated their public offerings with significant interest from cornerstone investors [16][19] - Five new stocks were listed, including Yunzhisheng, which saw a closing price increase of 44.59% on its first day [20][21][22][23] Group 3: Market Insights - The Hong Kong Stock Exchange raised over HKD 107 billion in the first half of 2025, with a 20% increase in the Hang Seng Index [24] - The biopharmaceutical sector has seen a resurgence, with 10 companies successfully listing in the first half of 2025, compared to only 12 for the entire previous year [25][26] - The total fundraising amount for the biopharmaceutical sector reached HKD 15.6 billion in the first half of 2025, indicating strong market interest [26][27]

根据睿兽分析监测数据，本周国内一级市场披露的融资事件93个，与上周相比增加5个，其中已披露 融资金额的事件34个，总融资规模为102.48亿元人民币，平均融资金额为3.01亿元人民币。 以下文章来源于睿兽Pro ，作者Bestla 睿兽Pro . 创业邦旗下横跨一二级市场的科创数据平台。实时投资数据、追踪产业创新。找数据、做分析、链资 源，就上睿兽分析。 全球投融资周报 睿兽分析每周整理当周最值得关注的国内外热门投融资事件，帮助大家及时了解全球市场动向。 一级市场投融资概览 行业分布 从融资事件数量来看，本周智能制造、人工智能、医疗健康领域融资最活跃。分别为智能制造21 个、人工智能19个、医疗健康9个。 从已披露金额事件的融资规模来看，能源电力最高，融资总规模约为44.34亿元人民币。其中多晶硅 生产商「永祥股份」完成近49.16亿人民币A轮融资。 永祥股份是通威集团控股的通威股份有限公司的一家大型民营科技型企业。公司主要业务涉及高纯晶 硅、高效硅片、聚氯乙烯（PVC）、离子膜烧碱、综合利用电石渣水。 其次是智能制造行业，已披露融资总额为26.03亿元人民币。 其中高性能GPU研发商「曦望 Sunrise」 ...

Group 1 - Shougang Longze has delayed its global offering and listing due to a civil lawsuit filed against it, which requires the company to provide more information to investors [1] - The company plans to issue a supplementary prospectus to update the listing timeline and related information [1] Group 2 - Hong Kong Stock Exchange has launched an order transmission service for its Integrated Fund Platform (IFP) to enhance efficiency in the fund distribution ecosystem [2] - The service integrates order processing for fund subscriptions and redemptions, welcoming 33 initial participants including distributors and fund companies [2] Group 3 - Eye care biotech company Bokan Vision Cloud-B saw its stock price drop significantly on its first trading day, closing down 38.61% from its IPO price of 10.1 HKD [3] - The decline may be attributed to market skepticism regarding its valuation and the current market environment for new listings [3] Group 4 - Anjoy Foods had a lackluster performance in the dark market, with its H-shares priced at 60 HKD and a total global offering of approximately 39.99 million shares [4] - Despite being the largest frozen food company in China with a market share of 6.6%, investor concerns about growth prospects and market competition may have impacted its initial reception [4]

拨康视云每股定价10.1港元，共发行6058.2万股股份，每手500股。该公司曾三次向港交所递交上市申 请，第四次终于闯关成功。 拨康视云是一家以创新驱动的临床阶段眼科生物科技公司，致力于内部发现、开发及商业化同类首创 （First-in-Class）及同类最佳（Best-in-Class）眼科疗法。 7月3日，眼科生物科技公司拨康视云-B（HK02592，股价6.2港元，市值52亿港元）正式登陆港交所主 板。上市首日，拨康视云低开低走，盘中跌幅一度超43%，截至收盘，跌幅仍达到38.61%。 拨康视云自主研发的核心产品CBT-001及CBT-009分别用于治疗翼状胬肉（一种良性增生性眼表疾病） 和青少年近视，CBT-001分别于2022年6月及2023年9月在美国及中国启动第3期多地区临床试验。公司 旗下的其他候选药物仍处于相对早期开发阶段，包括两款临床阶段候选药物和四款临床前阶段候选药 物。 2022年至2024年，拨康视云的研发开支持续增长，分别为0.15亿美元、0.28亿美元和0.38亿美元。其 中，核心产品CBT-001及CBT-009的临床研究开支分别为约760万美元、890万美元和1980万美元 ...

7月3日，拨康视云（CloudBreak Therapeutics）于香港交易所主板敲钟上市，股票代码：02592.HK，发 行价10.10港元/股。此次IPO市值达84.73亿港元，募集资金净额约5.22亿港元。这不仅宣告了一家创新 眼科药企成功登陆资本舞台，更是为全球亿万被眼科疾病困扰的患者敲响了希望之钟。本次上市募集的 资金将加速拨康视云核心产品管线的研发进程，特别是针对翼状胬肉的全球首创性药物CBT-001，正有 望改写全球眼科治疗指南。 CBT-001是一种研究阶段滴眼剂治疗方法，有可能减缓或阻止翼状胬肉的进展。翼状胬肉，作为一种常 见的慢性炎症增生性眼表疾病，通常发生于眼角部结膜，逐渐侵袭至角膜，引起散光或遮挡瞳孔，从而 导致视力下降甚至致盲。据世界卫生组织发布的《世界视觉报告》所示，翼状胬肉的全球患病率为 10.2%，中国农村地区高达33%。根据相关文献，中国40岁及以上人群患病率为13.4%，且随着年龄增长 而不断升高。目前并没有治疗翼状胬肉的专门药物，临床以人工泪液、非甾体类、糖皮质激素滴眼液等 标签外用药为主，但现有的治疗药物未显示确切疗效且存在长期用药安全性风险问题。严重患者可通过 手术 ...

配发结果公告显示，拨康视云本次发售股份数目为60,582,000股股份，其中，香港公开发售的发售股份 数目（经重新分配后调整）为12,115,500股股份，国际发售的发售股份数目（经重新分配后调整）为 48,466,500股股份。拨康视云于上市时已发行的股份数目为838,892,874股股份。 | 發售股份及股本 | | | --- | --- | | 發售股份數目 | 60,582,000 | | 香港公開發售的發售股份數目(經重新分配後調整) | 12,115,500 | | 國際發售的發售股份數目(經重新分配後調整) | 48,466,500 | | 於上市時已發行的股份數目 | 838,892,874 | 拨康视云的最终发售价为10.10港元，所得款项总额为611.88百万港元，扣除按最终发售价计算的估计应 付上市费用89.67百万港元后，所得款项净额为522.21百万港元。 中国经济网北京7月3日讯 拨康视云制药有限公司（以下简称"拨康视云"，02592.HK）今日在港交所上 市，开盘即破发，报9.50港元。截至今日收盘，拨康视云报6.20港元，跌幅38.61%。 拨康视云是一间临床阶段眼科生物科技 ...

Core Viewpoint - Cloudbreak Pharma Inc. (拨康视云) successfully listed on the Hong Kong Stock Exchange on July 3, 2025, raising approximately HKD 612 million through its IPO, with a strong demand reflected in the subscription rates [3][6]. Group 1: IPO Details - The IPO involved a global offering of 60.582 million shares, representing 7.22% of the total shares post-issue, priced at HKD 10.10 per share [3]. - The public offering was oversubscribed by 78.78 times, while the international offering saw a subscription rate of 0.89 times [3]. - Two cornerstone investors participated, committing a total of approximately USD 28.8 million, which accounted for 29.25% of the global offering [3]. Group 2: Shareholder Structure - The largest single shareholder is Dr. Ni Jinsong, holding approximately 20.86%, followed by his wife, Ms. Bing Leng, with 1.32%, totaling 22.18% [4]. - Other significant shareholders include Van Son Dinh (7.14%), Yang Rong (1.76%), and Li Jun Zhi (4.14%), along with various institutional investors [4][5]. Group 3: Company Overview - Established in 2015, Cloudbreak Pharma is an innovative clinical-stage ophthalmic biotechnology company focused on developing novel and differentiated therapies [6]. - The company has a pipeline of eight candidate drugs targeting major eye diseases, with four in clinical stages and four in preclinical stages [6]. - Key products include CBT-001 and CBT-004, which may be the first global treatments for pterygium and vascularized eyelid lesions, respectively [6]. Group 4: Market Performance - As of the midday close, Cloudbreak Pharma's stock was priced at HKD 7.04, with a total market capitalization of approximately HKD 5.906 billion [7][8].

Group 1: Company Developments - Bolekan Vision Cloud-B has launched its IPO on the Hong Kong Stock Exchange, with approximately 60.58 million shares available for global sale at a price of HKD 10.10 per share, indicating the company's confidence in its value [1] - Stand Robot has submitted its listing application to the Hong Kong Stock Exchange, focusing on industrial intelligent mobile robot solutions, despite currently being in a loss-making position [2] - Chengtai Technology has filed its prospectus with the Hong Kong Stock Exchange, specializing in millimeter-wave radar products, with projected revenues increasing from 0.58 billion to 3.48 billion from 2022 to 2024 [4] Group 2: Financial Performance - China Wangwang reported revenues of approximately 23.51 billion for the fiscal year ending March 31, 2025, a slight decrease of 0.3% year-on-year, while profit attributable to equity holders increased by 8.6% to 4.34 billion [3]

Group 1 - Cloudbreak Pharma Inc. (referred to as "Cloudbreak") plans to issue 60.582 million H-shares from June 24 to June 27, with an expected listing date on the Hong Kong Stock Exchange on July 3, 2025 [1][3] - The offering price is set at HKD 10.10 per share, aiming to raise approximately HKD 612 million, with a net fundraising amount of about HKD 522 million [3] - Key investors include Fuzhi Holdings Limited and The Reynold Lemkins Group (Asia) Limited, which collectively subscribed for approximately USD 28.8 million worth of shares [3] Group 2 - Cloudbreak is a clinical-stage ophthalmic biotechnology company focused on developing various therapies, with two core products: CBT-001 for treating pterygium and CBT-009 for juvenile myopia [5] - The company has other candidate drugs in early development stages, including two clinical-stage candidates and four preclinical-stage candidates [5] - Revenue projections for Cloudbreak are approximately zero for 2022 and 2023, with an expected revenue of USD 10 million in 2024; net losses are projected at USD 66.838 million, USD 129 million, and USD 99.13 million for the respective years [5] Group 3 - The funds raised from the IPO will be allocated to the continued clinical development of core product CBT-001, regulatory filing, and approval-related research, as well as costs associated with the development of CBT-009 [5]